News

Allon reports 2011 audited operating results and updates 2012 plans

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) today announced its audited operating results for 2011 and updated clinical development plans for 2012. Gordon McCauley, Allon’s President and CEO, said the Company’s most significant achievement in 2011 was the completion of enrollment in th... Continue reading →

Allon Therapeutics secures $2.5 million bridge financing with major shareholder

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today it has secured a bridge financing to strengthen the Company’s financial resources as it continues on schedule with its pivotal clinical trial investigating lead neuroprotective drug candidate davunetide as a potential treatment ... Continue reading →

Allon broadens intellectual property with new patent

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that it has been granted a patent relating to the use of Allon’s drug candidates, including lead drug candidate davunetide and pipeline product AL-309, to treat certain types of peripheral neurotoxicity. This new Australian pate... Continue reading →

New publication describes Allons davunetide as the most advanced global drug candidate for PSP

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that a review of davunetide as a potential treatment for progressive supranuclear palsy (PSP) was published in the February edition of Neuropsychiatric Disease and Treatment. The article describes davunetide as the most advanced... Continue reading →

Allons Data Safety Monitoring Board recommends continuation of pivotal clinical trial

VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley will present an update of the Company’s progress on Tuesday, February 14th at the 14th Annual BIO CEO & Investor Conference in New York City. During that presentation, McCauley will also discuss the latest ... Continue reading →

← Older posts Newer posts →